These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
393 related articles for article (PubMed ID: 19837760)
1. 18F-FDG small-animal PET/CT differentiates trastuzumab-responsive from unresponsive human breast cancer xenografts in athymic mice. McLarty K; Fasih A; Scollard DA; Done SJ; Vines DC; Green DE; Costantini DL; Reilly RM J Nucl Med; 2009 Nov; 50(11):1848-56. PubMed ID: 19837760 [TBL] [Abstract][Full Text] [Related]
2. Micro-SPECT/CT with 111In-DTPA-pertuzumab sensitively detects trastuzumab-mediated HER2 downregulation and tumor response in athymic mice bearing MDA-MB-361 human breast cancer xenografts. McLarty K; Cornelissen B; Cai Z; Scollard DA; Costantini DL; Done SJ; Reilly RM J Nucl Med; 2009 Aug; 50(8):1340-8. PubMed ID: 19617342 [TBL] [Abstract][Full Text] [Related]
3. Small-animal SPECT/CT of HER2 and HER3 expression in tumor xenografts in athymic mice using trastuzumab Fab-heregulin bispecific radioimmunoconjugates. Razumienko EJ; Scollard DA; Reilly RM J Nucl Med; 2012 Dec; 53(12):1943-50. PubMed ID: 23096164 [TBL] [Abstract][Full Text] [Related]
4. Antitumor effects and normal tissue toxicity of 111In-labeled epidermal growth factor administered to athymic mice bearing epidermal growth factor receptor-positive human breast cancer xenografts. Chen P; Cameron R; Wang J; Vallis KA; Reilly RM J Nucl Med; 2003 Sep; 44(9):1469-78. PubMed ID: 12960194 [TBL] [Abstract][Full Text] [Related]
5. The level of insulin growth factor-1 receptor expression is directly correlated with the tumor uptake of (111)In-IGF-1(E3R) in vivo and the clonogenic survival of breast cancer cells exposed in vitro to trastuzumab (Herceptin). Cornelissen B; McLarty K; Kersemans V; Reilly RM Nucl Med Biol; 2008 Aug; 35(6):645-53. PubMed ID: 18678349 [TBL] [Abstract][Full Text] [Related]
6. 18F-FDG PET/CT for early prediction of response to neoadjuvant lapatinib, trastuzumab, and their combination in HER2-positive breast cancer: results from Neo-ALTTO. Gebhart G; Gámez C; Holmes E; Robles J; Garcia C; Cortés M; de Azambuja E; Fauria K; Van Dooren V; Aktan G; Coccia-Portugal MA; Kim SB; Vuylsteke P; Cure H; Eidtmann H; Baselga J; Piccart M; Flamen P; Di Cosimo S J Nucl Med; 2013 Nov; 54(11):1862-8. PubMed ID: 24092940 [TBL] [Abstract][Full Text] [Related]
7. In vivo examination of (188)Re(I)-tricarbonyl-labeled trastuzumab to target HER2-overexpressing breast cancer. Chen KT; Lee TW; Lo JM Nucl Med Biol; 2009 May; 36(4):355-61. PubMed ID: 19423002 [TBL] [Abstract][Full Text] [Related]
8. Tumor uptake and tumor/blood ratios for [ Al-Saden N; Cai Z; Reilly RM Nucl Med Biol; 2018 Dec; 67():43-51. PubMed ID: 30390575 [TBL] [Abstract][Full Text] [Related]
9. Monitoring Src status after dasatinib treatment in HER2+ breast cancer with McKnight BN; Viola-Villegas NT Breast Cancer Res; 2018 Oct; 20(1):130. PubMed ID: 30359299 [TBL] [Abstract][Full Text] [Related]
10. 111In-cetuximab-F(ab')2 SPECT and 18F-FDG PET for prediction and response monitoring of combined-modality treatment of human head and neck carcinomas in a mouse model. van Dijk LK; Boerman OC; Franssen GM; Kaanders JH; Bussink J J Nucl Med; 2015 Feb; 56(2):287-92. PubMed ID: 25552666 [TBL] [Abstract][Full Text] [Related]
11. Positron-Emission Tomography of HER2-Positive Breast Cancer Xenografts in Mice with Al-Saden N; Lam K; Chan C; Reilly RM Mol Pharm; 2018 Aug; 15(8):3383-3393. PubMed ID: 29957952 [TBL] [Abstract][Full Text] [Related]
12. Dual-Receptor-Targeted Radioimmunotherapy of Human Breast Cancer Xenografts in Athymic Mice Coexpressing HER2 and EGFR Using 177Lu- or 111In-Labeled Bispecific Radioimmunoconjugates. Razumienko EJ; Chen JC; Cai Z; Chan C; Reilly RM J Nucl Med; 2016 Mar; 57(3):444-52. PubMed ID: 26429962 [TBL] [Abstract][Full Text] [Related]
13. Comparisons of [18F]-1-deoxy-1-fluoro-scyllo-inositol with [18F]-FDG for PET imaging of inflammation, breast and brain cancer xenografts in athymic mice. McLarty K; Moran MD; Scollard DA; Chan C; Sabha N; Mukherjee J; Guha A; McLaurin J; Nitz M; Houle S; Wilson AA; Reilly RM; Vasdev N Nucl Med Biol; 2011 Oct; 38(7):953-9. PubMed ID: 21982567 [TBL] [Abstract][Full Text] [Related]
14. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization. Basu S; Chen W; Tchou J; Mavi A; Cermik T; Czerniecki B; Schnall M; Alavi A Cancer; 2008 Mar; 112(5):995-1000. PubMed ID: 18098228 [TBL] [Abstract][Full Text] [Related]
15. Development and characterization of clinical-grade 89Zr-trastuzumab for HER2/neu immunoPET imaging. Dijkers EC; Kosterink JG; Rademaker AP; Perk LR; van Dongen GA; Bart J; de Jong JR; de Vries EG; Lub-de Hooge MN J Nucl Med; 2009 Jun; 50(6):974-81. PubMed ID: 19443585 [TBL] [Abstract][Full Text] [Related]
16. Preclinical and clinical evidence that Deoxy-2-[18F]fluoro-D-glucose positron emission tomography with computed tomography is a reliable tool for the detection of early molecular responses to erlotinib in head and neck cancer. Vergez S; Delord JP; Thomas F; Rochaix P; Caselles O; Filleron T; Brillouet S; Canal P; Courbon F; Allal BC Clin Cancer Res; 2010 Sep; 16(17):4434-45. PubMed ID: 20660574 [TBL] [Abstract][Full Text] [Related]